A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Trial details
- Registry ID
- NCT06072781
- Phase
- Phase 3
The FDA approved Letrozole (Femara) on 25 Jul 1997.
Drug identity checked against registry records
Also recorded as Femara
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerNCT06072781 | VSTM | Phase 3 | Recruiting | 2028-10-15Estimated |
| Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNCT07085767 | — | Phase 3 | Recruiting | 2028-12Estimated |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738 | OLMA | Phase 3 | Active not recruiting | 2026-10-31Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 1997-07-25Day | Letrozole | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA020726", "applicant_as_listed_by_fda": "NOVARTIS PHARMS", "brand_names": ["FEMARA"], "active_ingredients": ["LETROZOLE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "19970725", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |